The Potential of Dendrimers as Alzheimer’s Disease Nanotherapeutics – Evidence of Antiamyloidogenic Properties Against Aβ42
Débora A. Moreira, Sofia Duque Santos, Victoria Leiro, Ana Paula Pêgo · Alzheimer s & Dementia · 2023
Abstract Background Today, available therapies for Alzheimer’s disease (AD) fail to modify the disease progression for the major AD clinical stages [1]. Therefore, new therapeutic approaches are an urgent need. Within nanomedicine, the use of nanomaterials, and dendrimers in particular, pose as promising AD therapies [2]. Dendrimers are globular macromolecules, with a well‐defined and hyperbranched structure, controllable nanosize (1), they promoted Aβ fibrillation as more fibrils were present. More importantly, they were shown non‐toxic for neuroblastoma cells. Conclusion In conclusion, these results show that these dendrimers can interfere with Aβ fibrillation. Future studies will be performed to understand the mechanism of action of this new family of dendrimers.